Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
This story raises questions about governance, accountability, and American values.
Source: Quest Diagnostics
1 min read
/PRNewswire/ -- Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of
Original source:
Read at Quest DiagnosticsHow We See It
New Republican Times Editorial Board